儿童KMT2A重排急性淋巴细胞白血病研究进展  

Advances of KMT2A rearrangment acute lymphoblastic leukemia in children

作　　者：张永湛 尚倩雯 陆爱东[1] 张乐萍[1] Zhang Yongzhan;Shang Qianwen;Lu Aidong;Zhang Leping(Department of Pediatrics,Peking University People′s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院儿科,北京100044

出　　处：《中华实用儿科临床杂志》2024年第2期138-141,共4页Chinese Journal of Applied Clinical Pediatrics

基　　金：北京市卫生健康委员会北京市临床重点专科项目(2018)。

摘　　要：赖氨酸甲基转移酶2A(KMT2A)基因重排(KMT2A-r)是儿童急性淋巴细胞白血病(ALL)的一种高危基因亚型,复发率高,预后不良,使用传统化疗的疗效欠佳,改善儿童KMT2A-r ALL的治疗和预后仍是亟待解决的问题。近年来,随着人们对KMT2A-r机制的深入了解,将KMT2A-r ALL进行了更准确的风险分层,同时在免疫和靶向治疗方面也有了长足的进步。现就儿童KMT2A-r ALL的遗传和生物学特征、风险分层、治疗策略及预后进行综述,以期为临床工作和未来研究提供理论支持。Lysine methyltransferase 2A(KMT2A)rearrangement(KMT2A-r)is a high-risk gene subtype of acute lymphoblastic leukemia(ALL)in children with a high relapse rate,poor prognosis and suboptimal response to conventional chemotherapy.Improving the treatment and prognosis of childhood KMT2A-r ALL is an urgent problem.In recent years,with an in-depth understanding of the mechanism of KMT2A-r,more accurate risk stratification of KMT2A-r ALL has been carried out,and great progress has also been made in its immune and targeted therapy.In this article,the genetic and biological characteristics,risk stratification,treatment strategies and prognosis of children KMT2A-r ALL were reviewed in order to provide theoretical support for clinical work and future research.

关 键 词：急性淋巴细胞白血病 KMT2A基因重排 儿童 研究进展 

分 类 号：R733.71[医药卫生—肿瘤]